PASD1 Expression in Malaysian Hematological Malignancies Patients

Authors

  • Nor Adzimah Johdi UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.
  • Hanif Zulkhairi Mohd Said UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.
  • Rahman Jamal UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.
  • Mohd Razif Mohd Idris Cell Therapy Center, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.
  • Nor Azimah Ismail Cell Therapy Center, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.
  • Wan Fariza Wan Jamaludin Cell Therapy Center, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.
  • S. Fadila Abd Wahid Cell Therapy Center, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.
  • Muaatamarulain Mustangin Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.
  • Nur Maya Sabrina Tizen Laim Department of Pathology, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia.

DOI:

https://doi.org/10.54987/jobimb.v7i1.444

Keywords:

Lymphoma; PASD1; Expression; Antibody; DLBCL

Abstract

Per ARNT SIM domain containing 1 (PASD1) protein belongs to the Cancer Testis Antigen (CTA) family. It shows restricted expression in normal tissues but are highly expressed in cancer tissues. This study aims to further investigate PASD1 expression in Malaysian hematological malignancies patients as a potential biomarker for disease progression and vaccine development. Formalin-fixed Paraffin-Embedded (FFPE) tissue specimens from hematological malignancies patients were labeled with anti-PASD1-1 and anti-PASD1-2 antibodies using immunohistochemistry method. Our results show that among DLBCL patients, 7 samples were positive for PASD1-1, 2 samples were positive for PASD1-2 while 3 samples were positive for both of the antibodies. In addition, only 1 sample from T-cell Lymphoblastic Lymphoma (TLL) showed positive staining with PASD1-1. Other classes of hematological malignancies did not show any positive staining with either antibody. Antibody PASD1-1 stained the membrane and cytoplasm of the tumor cells strongly. Moderate nuclear labeling was also observed in some cases of DLBCL with PASD1-2. PASD1-1 staining was more frequent compared to PASD1-2 in most of the samples. Positive PASD1 staining was observed in patients with age range between 36-71 years old, higher in male cases than female by 54% and higher in Malay patients compared to Chinese by 77%.  Due to its frequency, the PASD1_v1 protein may play a role in the DLBCL initiation and progression. A higher number of PASD1 staining in DLBCL samples compared to other lymphoma subtypes may suggest that PASD1 may represent a potential for DLBCL subtyping marker.

Downloads

Published

31.07.2019

How to Cite

Johdi, N. A., Mohd Said, H. Z., Jamal, R., Mohd Idris, M. R., Ismail, N. A., Wan Jamaludin, W. F., Abd Wahid, S. F., Mustangin, M., & Tizen Laim, N. M. S. (2019). PASD1 Expression in Malaysian Hematological Malignancies Patients. Journal of Biochemistry, Microbiology and Biotechnology, 7(1), 1–4. https://doi.org/10.54987/jobimb.v7i1.444

Issue

Vol. 7 No. 1 (2019)

Section

Articles

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).